Latest in Drugs: Rapamycin, Metformin and GLP-1s

Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa

BioPharm International Spyre Therapeutics’ half-life-extended anti-TL1A antibody SPY072 failed to meet its primary endpoints in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) in the Phase 2 SKYWAY basket trial, and the company will no longer develop the antibody in rheumatic diseases.¹ Spyre…

griffonnews.com
1,280 words

Why some nutrient deficiencies go undetected

A person slicing vegetables for a week's meal preparation at home. Dietitian Tricia L. Psota told Everyday Health that nutrient deficiencies alter basic cellular functions, including processes tied to digestion and metabolism. And that cellular connection has also drawn attention from…

trendhunter.com
171 words

Once-Weekly Pediatric Insulin

Novo Nordisk Receives FDA Approval for Children's Diabetes Treatment Novo Nordisk has expanded access to once-weekly pediatric insulin following FDA approval of Awiqli for children aged 10 and older with type 2 diabetes. The long-acting treatment replaces seven weekly basal insulin injections…

Drugs: Rapamycin, Metformin and GLP-1s

Drugs: Rapamycin, Metformin and GLP-1s in Longevity: the news, the names and what changed.

  • 14 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.